Abstract
Purpose: 2-Deoxy-2-[18F]fluoro-D-Glucose positron emission tomography (FDG-PET) stages patients with Hodgkin's disease (HD) and Non-Hodgkin's lymphoma (NHL) with higher accuracy than computed tomography (CT). We sought to determine whether integrated (hardware) fused PET/CT imaging results in further improvements in staging accuracy. Procedures: Seventy-three patients (age 51 ± 17 years, 37 female, 36 male) with HD (n = 20) or NHL (n = 53) undergoing staging were studied with an integrated PET/CT system. Image findings were verified by clinical follow up, additional imaging and when available, histology. Results: Thirty-four of 73 patients (46.5%) had evidence of disease and 39 were disease free as confirmed by clinical evaluation and follow-up for 41 ± 22 weeks (n = 73), including biopsy (n = 26), and other imaging modalities (n = 52) when available. A discordant image interpretation between PET and PET/CT occurred in seven patients (10%). PET/CT correctly upstaged two and downstaged five patients. Overall staging was accurate in 93% with PET/CT and 84% with PET (P = 0.03). Conclusion: Lymphoma is staged with higher accuracy using PET/CT than PET alone.
Original language | English |
---|---|
Pages (from-to) | 411-416 |
Number of pages | 6 |
Journal | Molecular Imaging and Biology |
Volume | 6 |
Issue number | 6 |
DOIs | |
State | Published - Nov 2004 |
Externally published | Yes |
Keywords
- FDG-PET
- Lymphoma
- PET/CT
- Software fusion
- Staging